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Clinical impact of serum bilirubin 
levels on kidney transplant 
outcomes
Juhan Lee1, Eun Jin Kim1, Jae Geun Lee1, Beom Seok Kim2, Kyu Ha Huh1, Myoung Soo Kim1, 
Soon Il Kim1, Yu Seun Kim1 & Dong Jin Joo1* 
Serum bilirubin, a potent endogenous antioxidant, has been associated with decreased risks of 
cardiovascular disease, diabetes, and kidney disease. However, the effects of serum bilirubin on 
kidney transplant outcomes remain undetermined. We analyzed 1628 patients who underwent 
kidney transplantations between 2003 and 2017. Patients were grouped into sex-specific quartiles 
according to mean serum bilirubin levels, 3–12 months post-transplantation. Median bilirubin levels 
were 0.66 mg/dL in males and 0.60 mg/dL in females. The intra-individual variability of serum bilirubin 
levels was low (9%). Serum bilirubin levels were inversely associated with graft loss, death-censored 
graft failure, and all-cause mortality, independent of renal function, donor status, and transplant 
characteristics. Multivariable analysis revealed that the lowest serum bilirubin quartile was associated 
with increased risk of graft loss (HR 2.64, 95% CI 1.67–4.18, P < 0.001), death-censored graft failure 
(HR 2.97, 95% CI 1.63–5.42, P < 0.001), and all-cause mortality (HR 2.07, 95% CI 1.01–4.22, P = 0.046). 
Patients with lower serum bilirubin were also at greater risk of rejection and exhibited consistently 
lower glomerular filtration rates than those with higher serum bilirubin. Serum bilirubin levels were 
significantly associated with transplantation outcomes, suggesting that bilirubin could represent a 
therapeutic target for improving long-term transplant outcomes.
Kidney transplantation is the treatment of choice for most patients with end-stage renal disease. Despite con-
siderable advances in short-term outcomes, long-term kidney transplantation outcomes remain  suboptimal1,2. 
The causes associated with late graft failure are complex and multifactorial. Although immunologic risks are 
important, non-immunologic factors, including cardiovascular disease, metabolic disturbances, the recurrence of 
native kidney disease, and endothelial dysfunction have also been associated with late graft  failure3,4. Therefore, 
the identification of a useful monitoring tool or therapeutic target for standard clinical practice, beyond the 
evaluation of graft function, donor-specific antibodies, and histologic findings, has been  difficult5,6.
Bilirubin has long been viewed as a useless metabolite produced by heme catabolism, with little or no physi-
ological function, but with potential toxicity. However, accumulating clinical observations have indicated that 
circulating bilirubin, at levels within the physiological range, may protect against cardiovascular disease, dia-
betes, and all-cause  mortality7–9. These findings have also been extended to protection against kidney disease 
 progression10,11. These beneficial effects have largely been attributed to the antioxidant property of  bilirubin12,13. 
Recent studies have further suggested that bilirubin may exert anti-inflammatory, immunomodulatory, and 
endothelial protective  effects14.
Despite the beneficial effects associated with circulating bilirubin levels, whether serum bilirubin levels affect 
long-term graft outcomes after kidney transplantation remains  unclear15. Therefore, we examined the association 
between serum bilirubin levels and graft and patient survival, graft function, and rejection in a large cohort of 
kidney transplant recipients.
Results
Baseline characteristics. A total of 1628 patients were included in this study, who underwent an average 
of 8.6 serum bilirubin tests per patients between 3 and 12 months after transplantation (Fig. 1). The distribution 
of mean serum bilirubin levels, according to quartile and sex, is shown in Fig. 2. Mean serum bilirubin levels in 
this cohort were right-skewed, with median levels of 0.66 mg/dL (IQR 0.50–0.85) in males and 0.60 mg/dL (IQR 
0.50–0.74) in females. The intra-individual variability of serum bilirubin levels was low, at 9%.
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The baseline characteristics of patients according to serum bilirubin quartiles are presented in Table 1. No 
significant differences in age, sex, body mass index, and dialysis vintage were observed among the groups. Hepatic 
synthesis markers were not significantly different among groups. Patients with high serum bilirubin levels tended 
to receive transplants from younger donors. Patients with low serum bilirubin levels received more deceased 
donor kidney transplants and were more likely to develop delayed graft function. Although mean donor eGFR of 
the lowest bilirubin group was significantly lower than other groups, mean donor eGFR of the group was greater 
than 90 mL/min/1.73m2. The median follow-up duration was 87 months (IQR 51.3–127.0).
Table 2 shows the immunosuppressive treatment in our cohort. No significant differences in induction regi-
men were observed among the groups. Tacrolimus was used more frequently in patients with low serum bilirubin 
Figure 1.  Study flow chart.
Figure 2.  Distribution of serum bilirubin levels by sex. (A) Male. (B) Female.
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Table 1.  Baseline characteristics of patients, stratified by sex-specific serum bilirubin levels.
Quartile 1 (N = 413) Quartile 2 (N = 371) Quartile 3 (N = 446) Quartile 4 (N = 398) P
Female, n (%) 163 (39.5) 134 (36.1) 194 (43.5) 163 (41.0) 0.189
Age, years 44.4 ± 12.4 44.7 ± 11.8 45.4 ± 11.3 45.9 ± 11.1 0.235
Mean level of bilirubin, mg/dL 0.4 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 1.1 ± 0.3  < 0.001
Body mass index, kg/m2 22.7 ± 3.2 22.6 ± 3.5 22.2 ± 3.1 22.4 ± 3.3 0.232
HLA mismatch number 2.9 ± 1.5 3.0 ± 1.5 2.9 ± 1.5 2.7 ± 1.5 0.083
Re-transplant, n (%) 36 (8.7) 32 (8.6) 35 (7.8) 28 (7.0) 0.54
Dialysis vintage, months 39.5 ± 50.1 37.0 ± 48.3 34.7 ± 46.4 38.3 ± 54.5 0.563
Hepatic synthesis marker
Albumin, g/dL 4.3 ± 0.4 4.4 ± 0.4 4.4 ± 0.3 4.4 ± 0.3 0.377
Prothrombin time, INR 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 1.0 ± 0.2 0.301
Female donor, n (%) 205 (49.6) 197 (53.1) 212 (47.5) 202 (50.8) 0.455
Donor age, years 44.4 ± 12.9 42.4 ± 12.0 41.3 ± 12.3 40.3 ± 12.0  < 0.001
Donor eGFR, ml/min/1.73m2 91.5 ± 29.4 95.7 ± 29.7 98.7 ± 26.5 101.2 ± 28.5  < 0.001
Deceased donor, n (%) 140 (33.9) 108 (29.1) 99 (22.2) 89 (22.4)  < 0.001
Cause of death, n (%) 0.736
 Hypoxia 31 (22.1) 21 (19.4) 27 (27.3) 22 (24.7)
 Cerebrovascular disease 73 (52.1) 54 (50.0) 52 (52.5) 40 (44.9)
 Trauma 32 (22.9) 30 (27.8) 18 (18.2) 24 (27.0)
 CNS tumor 2 (1.4) 1 (0.9) 2 (2.0) 1 (1.1)
 Others 2 (1.4) 2 (1.9) 0 2 (2.2)
Delayed graft function, n (%) 45 (10.9) 27 (7.3) 31 (7.0) 20 (5.0) 0.015
Renin-angiotensin system 
inhibitors 200 (48.4) 149 (40.2) 152 (34.1) 135 (33.9)  < 0.001
HMG CoA reductase inhibitors 212 (51.3) 207 (55.8) 244 (54.7) 259 (65.1)  < 0.001
Table 2.  Immunosuppression, stratified by sex-specific serum bilirubin levels.
Quartile 1 (N = 413) Quartile 2 (N = 371) Quartile 3 (N = 446) Quartile 4 (N = 398) P
Induction agent, n (%)
 No 59 (14.3) 44 (11.9) 59 (13.2) 53 (13.3) 0.709
 Basiliximab 343 (83.1) 317 (85.4) 381 (85.4) 338 (84.9)
 Anti-thymocyte globulin 11 (2.7) 10 (2.7) 6 (1.3) 7 (1.8)
Maintenance agent, n (%) 0.007
 Tacrolimus 337 (81.6) 280 (75.5) 333 (74.7) 284 (71.4)
 Cyclosporine 76 (18.4) 91 (24.5) 113 (25.3) 114 (24.4)
Tacrolimus level, ng/mL
 1 month 6.7 ± 3.4 6.4 ± 3.4 6.3 ± 2.9 5.9 ± 3.1 0.004
 3 months 6.6 ± 3.1 6.3 ± 2.7 6.3 ± 2.6 5.8 ± 2.4 0.002
 6 months 6.5 ± 2.9 6.4 ± 2.8 6.2 ± 2.4 5.9 ± 2.2 0.021
 12 months 6.1 ± 2.7 6.1 ± 2.6 6.2 ± 2.7 5.9 ± 2.5 0.271
Tacrolimus dose, mg/day
 1 month 5.8 ± 3.5 4.9 ± 3.0 4.9 ± 3.0 4.5 ± 2.7  < 0.001
 3 months 5.3 ± 3.0 4.6 ± 2.5 4.7 ± 2.7 4.1 ± 2.4  < 0.001
 6 months 5.0 ± 2.9 4.4 ± 2.3 4.4 ± 2.5 4.0 ± 2.3  < 0.001
 12 months 4.7 ± 2.8 3.9 ± 2.1 4.0 ± 2.3 3.7 ± 2.1  < 0.001
Cyclosporine level, ng/mL
 1 month 161.8 ± 65.8 156.3 ± 66.7 163.5 ± 63.1 147.0 ± 51.7 0.259
 3 months 120.6 ± 57.8 121.7 ± 41.3 122.8 ± 40.5 130.0 ± 47.3 0.584
 6 months 98.1 ± 44.5 112.5 ± 68.2 117.7 ± 50.5 118.2 ± 56.6 0.22
 12 months 101.7 ± 58.0 111.2 ± 75.0 114.7 ± 62.5 112.6 ± 46.0 0.71
Cyclosporine dose, mg/day
 1 month 241.4 ± 97.8 230.1 ± 88.6 242.7 ± 89.0 234.2 ± 88.6 0.74
 3 months 188.8 ± 85.6 189.5 ± 69.5 202.0 ± 68.3 206.9 ± 76.3 0.247
 6 months 153.1 ± 87.9 164.3 ± 73.9 168.9 ± 72.6 170.7 ± 62.8 0.198
 12 months 136.7 ± 81.4 147.9 ± 62.4 147.2 ± 58.0 149.4 ± 63.0 0.093
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levels than in those with high levels. There were significant differences in the tacrolimus doses and trough levels, 
whereas there were no significant differences in the cyclosporine doses and trough levels among the groups.
Risk factors associated with the lowest serum bilirubin levels. To confirm the risk factors associ-
ated with low serum bilirubin levels, we performed multivariable logistic regression analyses using the lowest 
serum bilirubin quartile as a binary, dependent variable. In the multivariable analysis, recipient age, tacrolimus 
use, renin-angiotensin system inhibitor use, and hemoglobin, total cholesterol, and high-density lipoprotein 
cholesterol levels at 3 months post-transplantation remained associated with low serum bilirubin levels (Table 3).
Serum bilirubin and graft outcomes. As shown in Fig.  3A, overall graft survival was significantly 
impaired with decreasing serum bilirubin levels (P < 0.001). The 10-year graft survival rates were 91.5% in the 
highest quartile (Q4), 89.8% in the second quartile (Q3), 84.5% in the third quartile (Q2), and 76.8% in the 
lowest quartile (Q1; P < 0.001). Death-censored graft survival was also significantly different among the groups 
(Fig. 3B). Recipients with high bilirubin levels had the best death-censored graft survival, whereas recipients 
with low bilirubin levels had the worst death-censored graft survival. Compared with the highest bilirubin 
group, the lowest and third quartile groups were significantly associated with graft loss and death-censored graft 
failure (Table 4). The risks for graft loss and death-censored graft failure in the lowest bilirubin group remained 
significant, although attenuated, in the fully adjusted model (hazard ratio [HR] 2.64; 95% confidence interval 
[CI] 1.67–4.18; and HR 2.96; 95% CI 1.62–5.40, respectively).
During follow-up, 66 (4.1%) patients died, including 34 who died of infectious causes, 12 who died of malig-
nancies, 7 who died of cardiovascular causes, and 13 who died of other causes. Compared with the highest 
bilirubin group, the lowest bilirubin group was significantly associated with all-cause mortality (Fig. 3C). A 
multivariable Cox regression confirmed that the lowest serum bilirubin group was independently associated 
with higher mortality (HR, 2.07; 95% CI, 1.01–4.22).
Serum bilirubin levels and graft rejection. During the follow-up period, 769 rejection episodes 
occurred in 286 patients (294 early-onset and 475 late-onset rejection episodes). The incidences of early-onset 
rejection (within 3 months from transplant) in Q1, Q2, Q3, and Q4, were 12.1%, 7.3%, 6.1%, and 4.0%, respec-
tively (P < 0.001). The ten-year cumulative probabilities for late-onset rejection (> 3 months after transplant), in 
Q1, Q2, Q3, and Q4, were 28.6%, 26.0%, 17.1%, and 16.4%, respectively (Fig. 4, P < 0.001). A greater proportion 
of patients in the Q1 and Q2 groups (9.4% and 9.7%, respectively) experienced multiple late-onset rejection 
episodes compared with those in the Q3 and Q4 groups (6.1% and 4.0%, respectively; P < 0.001).
Serum bilirubin and graft renal function. The mean estimated glomerular filtration rate (eGFR) was 
consistently lower in the lowest bilirubin (Q1) and third quartile groups (Q2) than in the highest bilirubin 
(Q4) and second quartile groups (Q3), throughout the follow-up period (Fig. 5). The mean eGFRs at 5-years 
post-transplantation were 63.5 ± 22.5, 68.2 ± 21.0, 71.4 ± 19.7, and 70.5 ± 18.7  mL/min/1.73  m2, respectively 
(P < 0.001). The significant effects of serum bilirubin on graft function were maintained, regardless of donor 
status (data not shown).
Table 3.  Risk factors associated with the lowest serum bilirubin quartile.
Variable
Univariate Multivariate
OR (95% CI) P OR (95% CI) P
Age, years 0.99 (0.98–1.00) 0.136 0.97 (0.96–0.99)  < 0.001
Female 0.96 (0.77–1.21) 0.735
Body mass index, kg/m2 1.02 (0.99–1.06) 0.146 1.03 (0.97–1.09) 0.397
HLA mismatch (per 1 mismatch) 1.05 (0.97–1.13) 0.203
Deceased donor (versus living) 1.59 (1.25–2.03)  < 0.001 1.19 (0.76–1.85) 0.453
Donor age, y 1.02 (1.01–1.03)  < 0.001 1.01 (0.99–1.02) 0.444
Donor eGFR, ml/min/1.73m2 0.99 (0.98–0.99)  < 0.001 1.00 (0.99–1.01) 0.159
Tacrolimus (versus cyclosporine) 1.57 (1.19–2.08) 0.002 1.86 (1.12–3.09) 0.017
Renin-angiotensin system inhibitors 1.68 (1.34–2.10)  < 0.001 1.47 (1.03–2.11) 0.035
HMG CoA reductase inhibitors 0.75 (0.60–0.94) 0.012 1.00 (0.69–1.45) 0.998
Laboratory findings at 3 months
eGFR, ml/min/1.73m2 0.98 (0.97–0.98)  < 0.001 0.99 (0.98–1.00) 0.141
Hemoglobin, mg/dL 0.63 (0.58–0.68)  < 0.001 0.60 (0.52–0.69)  < 0.001
Phosphorus, mg/dL 0.92 (0.76–1.11) 0.388
Uric acid, mg/dL 1.12 (1.03–1.23) 0.008 0.91 (0.80–1.03) 0.127
Total cholesterol, mg/dL 1.00(1.00–1.01) 0.058 1.01 (1.00–1.01) 0.004
HDL cholesterol, mg/dL 0.98 (0.97–0.99)  < 0.001 0.98 (0.96–0.99) 0.001
Triglyceride, mg/dL 1.01 (1.00–1.01)  < 0.001 1.00 (1.00–1.01) 0.612
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Figure 3.  Graft and patient survival according to serum bilirubin level: (A) overall graft survival, (B) death-
censored graft survival, and (C) patient survival.
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Table 4.  Association between serum bilirubin levels and graft loss, death-censored graft failure, and mortality. 
Model 1 adjusted for age, sex, and BMI. Model 2 adjusted for age, sex, BMI, donor status (deceased versus 
living), HLA mismatch, donor age, donor eGFR, and donor sex. Model 3 adjusted for age, sex, BMI, donor 
status (deceased versus living), HLA mismatch, donor age, donor eGFR, donor sex, dialysis duration, and 
eGFR.
Variables
Model 1 Model 2 Model 3
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Graft loss
Bilirubin group (4th quartile) 1 [Reference] 1 [Reference] 1 [Reference]
 1st quartile 3.37 (2.16–5.26)  < 0.001 2.97 (1.89–4.67)  < 0.001 2.64 (1.67–4.18)  < 0.001
 2nd quartile 2.06 (1.27–3.34) 0.003 1.82 (1.12–2.97) 0.016 1.74 (1.07–2.84) 0.026
Death-censored graft failure
Bilirubin group (4th quartile) 1 [Reference] 1 [Reference] 1 [Reference]
 1st quartile 3.81 (2.12–6.84)  < 0.001 3.51 (1.94–6.36)  < 0.001 2.97 (1.63–5.42)  < 0.001
 2nd quartile 2.24 (1.19–4.24) 0.013 2.03 (1.07–3.85) 0.029 1.87 (0.99–3.56) 0.055
All-cause mortality
Bilirubin group (4th quartile) 1 [Reference] 1 [Reference] 1 [Reference]
 1st quartile 2.64 (1.32–5.27) 0.006 2.17 (1.07–4.37) 0.031 2.07 (1.01–4.22) 0.047
 2nd quartile 1.64 (0.77–3.50) 0.204 1.37 (0.64–2.95) 0.417 1.40 (0.65–3.00) 0.399
Figure 4.  Late-onset rejection according to serum bilirubin level.
Figure 5.  Changes in graft function according to serum bilirubin level.
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Discussion
In this study, we found that lower serum bilirubin levels were associated with higher risks of graft loss, death-
censored graft failure, and all-cause mortality, after adjustment for graft function, donor status, human leukocyte 
antigen (HLA) mismatch, and transplant characteristics. Furthermore, patients with lower serum bilirubin levels 
were at increased risk of rejection and exhibited consistently lower eGFR values compared with those with higher 
serum bilirubin levels.
Bilirubin, a breakdown product of heme catabolism, has long been regarded as a useless and toxic metabolite. 
However, growing evidence has shown that bilirubin exerts antioxidant, anti-inflammatory, and lipid peroxida-
tion inhibitory  effects12,13,16. Large epidemiological studies have shown that mildly elevated bilirubin levels are 
associated with decreased risks of cardiovascular and metabolic  diseases8,9,17. In addition, animal experiments 
and clinical studies have found that bilirubin can prevents the progression of renal disease, which is characterized 
by increased oxidative stress, inflammatory activation, and metabolic  disturbances11. These previous findings 
suggested that serum bilirubin levels might be associated with graft outcomes after kidney  transplantation15.
The causes of graft failure are heterogeneous and  multifactorial3,4. Non-immunological injuries, including 
oxidative stress, cardiovascular and metabolic disturbances, and endothelial dysfunction, can significantly con-
tribute to graft failure. Despite the introduction of potent immunosuppression, graft rejection and alloimmune 
injury continue to play important roles in graft  failure18. As mentioned above, accumulating evidence has shown 
that bilirubin exerts a protective role against renal disease progression, through various  mechanisms10,11. Bilirubin 
also has an immunomodulatory effect, which is expected to reduce graft rejection after kidney  transplantation14,15. 
However, scarce data exist regarding the association between serum bilirubin levels and kidney transplant 
 outcomes19.
Our findings suggested that serum levels of bilirubin are inversely associated with graft and patient survival. 
Previous studies have assessed the association between serum bilirubin levels and graft outcomes in kidney 
transplant  recipients19,20. However, they used a single serum bilirubin measurement, taken at one time point after 
transplantation, and more patients received cyclosporine in these studies, in contrast with the current clinical 
practice of tacrolimus administration. In addition, the range of time between transplantation and enrollment 
was wide (IQR, 2.6–11.4 years)19. Compared with previous studies, we measured serum bilirubin levels several 
times after transplantation, within the same time period (3–12 months) for all patients, and confirmed the low 
intra-individual variability in serum bilirubin levels. Cardiovascular disease-related mortality was found to be 
significantly lower in this study cohort. The high proportion of living donor transplants, the relatively young 
ages of included patients, and the reduced prevalence of cardiovascular risk factors may explain the low cardio-
vascular disease-related mortality among our cohort. Thus, our findings suggested a potential beneficial effect 
of circulating bilirubin for kidney transplant patients, beyond cardiovascular protection.
Despite significant advances in short-term outcomes after kidney transplantation, long-term outcomes 
have not improved  substantially1,2. The impact of late-onset rejections on long-term graft outcomes has been 
increasingly recognized as immunologic assays and diagnostic criteria have  improved18. We found that low 
serum bilirubin levels were associated with late-onset rejection. In addition, significantly more patients with 
low bilirubin levels experienced multiple rejection episodes than those with higher bilirubin levels. Bilirubin has 
immunomodulatory activities that can reduce effector T-cell responses, intercept the complement cascade, and 
promote the expansion of the regulatory T-cell population, which may play beneficial roles in the prevention of 
graft  rejection15,21,22. In addition, bilirubin inhibits the cell-surface expression of the major histocompatibility 
complex (MHC) II class molecules B7 and  CD2823,24. Animal model studies have shown that bilirubin can induce 
tolerance after  transplantation25. Lee et al. also found that lower serum bilirubin levels 1 year after transplantation 
were associated with increased graft  rejection20.
To the best of our knowledge, this study represents the largest cohort study conducted to evaluate the effects of 
serum bilirubin on transplant outcomes after kidney transplantation. Although determining causality is beyond 
the scope of this study, multiple mechanisms have been proposed to explain the beneficial effects of  bilirubin9,11,14. 
To date, the insolubility of bilirubin has limited its clinical application, but several therapeutic approaches are 
continuously being  developed26,27. The potential beneficial effects on bilirubin indicate that bilirubin could repre-
sent a valuable target for pharmacologic interventions designed to improve long-term transplant  outcomes9,27–29.
Our study has several limitations. First, this study was performed as a retrospective study at a single institu-
tion. However, this study design allowed us to ascertain granular data and maintain homogeneity during the 
follow-up protocol and the application of immunosuppressive regimens. Second, this study included a large 
number of living donor transplant patients with low cardiovascular risks; thus, our results might have limited 
generalizability. We may have underestimated the beneficial effects of circulating bilirubin on the transplant 
outcomes associated with cardiovascular protection. We also noted an imbalance of donor characteristics among 
groups. Although the impact of serum bilirubin on the transplant outcomes remained significant in the fully 
adjusted model including donor characteristics, the results of this study should be interpreted cautiously. Third, 
the lack of fractionation of total bilirubin into conjugated and unconjugated fractions limited the ability to evalu-
ate which bilirubin fraction was associated with graft outcomes. Finally, as with any observational study, we can 
neither prove causality nor exclude the possibility of potential confounders.
In conclusion, we found that serum bilirubin levels were inversely associated with graft and patient survival 
in kidney transplant recipients. Patients with lower serum bilirubin levels were also associated with increased 
risks of late-onset rejection and inferior graft function.
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Methods
Study population. A total of 2044 adult patients (aged ≥ 18 years) underwent kidney transplantation at the 
Severance Hospital, Seoul, Republic of Korea, between January 2003 and December 2017. Patients who under-
went multi-organ transplantations and HLA-incompatible kidney transplant recipients were excluded. We also 
excluded patients who experienced graft loss within 3 months, who were diagnosed with viral hepatitis, and who 
lacked sufficient data. After the exclusion of ineligible patients, 1628 kidney transplant recipients were enrolled 
in this study. Patients were grouped into sex-specific quartiles, based on mean serum bilirubin levels assessed 
between 3 and 12 months post-transplantation (Fig. 1).
Immunosuppression. Immunosuppression was performed as described  previously30. Most patients 
received induction immunosuppression with basiliximab or anti-thymocyte globulin. Maintenance immuno-
suppression consisted of calcineurin inhibitors (tacrolimus or cyclosporine), prednisolone, and mycophenolate 
mofetil (MMF). The initial tacrolimus dosage was administered orally, at 0.1 mg/kg, twice daily. Subsequent 
doses were adjusted to maintain a target trough concentration between 5 and 8 ng/mL. The initial oral dosage of 
cyclosporine was 5 mg/kg twice daily, and it was adjusted to achieve a trough level of 100–200 ng/mL. The initial 
dose of methylprednisolone (500–1000 mg) was gradually reduced to oral prednisolone (5–10 mg/day) during 
the first 3 weeks after transplantation. The initial dose of MMF was 1.0 g/day, which was subsequently adjusted 
to minimize adverse events, such as gastrointestinal trouble or neutropenia.
Clinical and laboratory measurements. Routine biochemical tests, including the assessment of total 
serum bilirubin, were performed every month for the first post-transplantation year, and every 3 months there-
after. Serum total bilirubin was measured using an absorptiometric assay with chemical oxidation by vanadic 
acid on an automatic analyzer. GFR was evaluated using the Chronic Kidney Disease Epidemiology Collabora-
tion Eq. 31.
Renal biopsies were performed in cases of acute allograft dysfunction (> 30% increase in serum creatinine 
levels compared with baseline or proteinuria > 500 mg/day). Allograft biopsy samples were processed using light, 
immunofluorescent, and electron microscopy at the time of biopsy. All acute rejections were confirmed by biopsy 
and classified according to the most recent Banff criteria at the time of  biopsy32.
Definition and study endpoints. Graft loss was defined as the return to long-term dialysis, re-transplan-
tation, or death with a functioning  graft33. Graft survival was calculated from the date of transplantation to the 
date of graft loss or December 31, 2019 (the end of the follow-up period). In cases of death with a functioning 
graft, graft survival was censored at the time of death. Patient survival was evaluated as the date of transplanta-
tion to the date of death or the last follow-up. Late-onset rejection was defined as any biopsy-confirmed rejection 
that occurred more than 3 months post-transplantation.
The primary study endpoint was graft loss. Secondary endpoints included death-censored graft failure, all-
cause patient mortality, late-onset rejection, and graft function.
Statistical analysis. Data were expressed as the frequency, the mean and standard deviation, or the median 
and interquartile range, depending on the data type. Chi-square or Fisher’s exact tests were used as appropri-
ate to compare categorical variables. Continuous variables were compared using one‐way analysis of variance, 
for parametric data, or the Kruskal–Wallis test, for nonparametric data. Multivariable logistic regression was 
performed using the lowest bilirubin group as an outcome variable. Covariates included baseline characteristics 
and laboratory findings at 3 months post-transplantation. Graft and patient survival rates were analyzed using 
Kaplan–Meier curves and the log-rank test. Cox proportional hazard regression models were used to evaluate 
the associations between serum bilirubin levels and time to graft loss, death-censored graft failure, and all-
cause mortality. Initial models were adjusted, a priori, for serum bilirubin level, age, sex, and body mass index. 
Extended models were further adjusted, a priori, for donor status (deceased versus living), HLA mismatch, 
donor age, and donor sex. Fully adjusted models were a priori adjusted for dialysis duration and eGFR. Statisti-
cal analyses were performed using SPSS software (version 25.0; SPSS Inc., Chicago, IL, USA), and P < 0.05 was 
considered significant.
Ethics statement. All study procedures were conducted in accordance with the Declaration of Helsinki 
and were approved by the Institutional Review Board of Severance Hospital (2020–1309-001). Informed consent 
was waived by the Institutional Review Board of Severance Hospital because of the study’s retrospective design.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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